Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Exevir Bio B.V.
BioCentury | Sep 13, 2024
Data Byte
PanTera largest Belgian A round to date
Only nine other biotechs have raised over $25 million since 2015
BioCentury | Dec 17, 2022
Management Tracks
Oschmann resigns as UCB chair
Plus: Papapetropoulos named president and CEO, and Weaver made general counsel at Organon
BioCentury | Oct 20, 2022
Management Tracks
5AM hires Anna Yaeger as head of public equities
Plus Scripps alum Maricich becomes Ashvattha CMO and updates from Alexion, Rewind, ExeVir and more
BioCentury | Jul 14, 2021
Deals
July 13 Quick Takes: Ionis gains oligonucleotide delivery tech from Bicycle; plus Nimbus, ISA and more
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) exercised its option to license from Bicycle Therapeutics Inc. (NASDAQ:BCYC) tissue -targeted delivery vehicles for oligonucleotide therapeutics that use a
BioCentury | Mar 17, 2021
Deals
March 17 Quick Takes: Merck-Amathus enter neurodegenerative disease collaboration; plus WuXi, Sana-Fujifilm, Rubius, Inflammatix, StrideBio and more
Amathus Therapeutics entered a strategic collaboration with Merck & Co. Inc. (NYSE:MRK) to develop small molecules for neurodegenerative diseases. Under the deal, Amathus will identify and conduct
BioCentury | Aug 1, 2020
Emerging Company Profile
VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology
ExeVir emerges with llama-based antibody platform, 1st program for COVID-19
Items per page:
1 - 7 of 7